Poland· PL-100539903
mCOMBRIAX
A medicinal product containing szczepionka mrna przeciw grypie i covid-19, registered in Poland by Moderna Biotech Spain, S.L..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Szczepionka mRNA przeciw grypie i COVID-19
- Manufacturer
- Moderna Biotech Spain, S.L.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1117099-a83d-4837-9871-02d6b157cf18 GET /v1/drugs/e1117099-a83d-4837-9871-02d6b157cf18?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dyspersja do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "8,3 mcg RNA hemaglutyniny na szczep wirusa grypy + 6,7 mcg RNA wirusa SARS-CoV-2",
"packaging": "Rp ¦ EU/1/26/2028/001 ¦ 167489\n1 amp.-strzyk. 0,32 ml\nRp ¦ EU/1/26/2028/002 ¦ 167490\n10 amp.-strzyk. 0,32 ml",
"substance": "Szczepionka mRNA przeciw grypie i COVID-19 8,3 mcg RNA hemaglutyniny na szczep wirusa grypy + 6,7 mcg RNA wirusa SARS-CoV-2",
"common_name": "Szczepionka mRNA przeciw grypie i COVID-19",
"pl_product_id": "100539903",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about szczepionka mrna przeciw grypie i covid-19.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.